IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for ‘Best Mobile App for Patient Engagement'
IQVIA's breakthrough Health Research Space platform allows direct-to-patient data collection and engagement with patient-facing mobile apps that helps patients and their caregivers participate in decentralized clinical trials around the world. The platform is configurable, multilingual and compatible with web, iOS and Android and is available across many geographic regions, increasing patient access to participate in clinical research.
The app improves trial participant engagement and retention and includes robust privacy and security features. By facilitating direct-to-patient data collection, the platform helps to generate real-world evidence for new medicines and innovative medical devices and diagnostics.
"IQVIA's mobile app is essential for improving engagement and reaching patients and caregivers. It lets them connect from any location, essentially meeting them where they are, with strong patient privacy safeguards," said Rob Kotchie, president of Real World Solutions at IQVIA. "Our platform meets the needs of real-world decentralized and hybrid studies throughout the drug and device development life cycle, helps to reduce patient burden and enables long-term follow-up. It ensures that patients can participate in studies more easily and for extended periods.'
The MedTech Breakthrough Awards, a program of Tech Breakthrough, an independent market intelligence organization, recognizes excellence and innovation in the health and medical technology industry. The program honors the companies, products and solutions driving meaningful progress and improving patient care. This year's program received 4,500 entries across all awards, showcasing the global impact and momentum of the digital healthcare industry today.
'There's a growing expectation for life sciences organizations to focus on patient-centered and long-term outcome data collection,' said Steve Johansson, managing director, Tech Breakthrough. 'However, traditional clinical study participation is not possible for all patient populations and includes barriers, such as the need to travel to a research site for in-person appointments. IQVIA's innovative patient-facing app helps reduce barriers to patient participation and provides effective, efficient data collection and engagement. Its streamlined processes make it easy for individuals to engage and take a more active role in managing their health. Congratulations to the IQVIA team on recognition of this solution.'
To learn more about the IQVIA Health Research Space solution, visit our site.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
About the MedTech Breakthrough Awards
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical and health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information, visit MedTechBreakthrough.com.
Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Why Reddit Stock Is Skyrocketing Today
Key Points Reddit reported sales and earnings performances for the second quarter that crushed Wall Street's expectations. The company also issued very encouraging guidance for Q3. Reddit is seeing strong sales tailwinds connected to the importance of its platform in training AI models. 10 stocks we like better than Reddit › Reddit (NYSE: RDDT) stock is surging Friday despite strong bearish pressures shaping the broader market. The company's share price was up 21.1% as of 11:40 a.m. ET. At the same point in the day's trading, the S&P 500 was down 1.7%, and the Nasdaq Composite had fallen 2.2%. While the broader market is seeing big sell-offs in response to a weaker-than-expected July jobs report, Reddit is enjoying huge valuation gains on the heels of its recent second-quarter report. In addition to beating sales and earnings targets for the period, the company also issued very strong forward guidance. Reddit stock surges as Q2 results crush expectations Reddit's Q2 report arrived with plenty for investors to be excited about. The company posted earnings per share of $0.45 on revenue of $500 million, crushing the average analyst estimate's call for per-share earnings of $0.19 on sales of $426 million. Revenue was up roughly 78% year over year in the quarter, and daily active users on its platform rose 21% year over year to reach 110 million. Even better, it seems strong momentum is poised to continue in the near term. What's next for Reddit? Reddit is guiding for sales to come in between $535 million and $545 million in the current quarter -- good for growth of roughly 55% year over year at the midpoint of the guidance range. Non-GAAP (adjusted) earnings before interest, taxes, depreciation, and amortization (EBITDA) is projected to be between $185 million and $195 million -- improving from $94.1 million in last year's quarter. While Reddit is pivoting away from its focus on driving growth through the user economy, the company is seeing some very strong tailwinds connected to artificial intelligence (AI). CEO Steve Huffman noted that Reddit continues to be the "most cited domain for AI across all models," and the company could continue to post very strong results and crush expectations if that tailwind holds. Should you buy stock in Reddit right now? Before you buy stock in Reddit, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Reddit wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Reddit Stock Is Skyrocketing Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
18 minutes ago
- Business Wire
BioConsortia Closes Financing to Accelerate Launch of Next-Generation Nitrogen-Fixing Biofertilizer and Fuel Global Expansion
BUSINESS WIRE)--BioConsortia, Inc., a leader in microbial innovation for sustainable agriculture, announced today it has secured $15 million in funding from its long-standing internal investors, led by Otter Capital and affiliated funds. 'This investment, one in a series of recurring financings from our internal investors, reflects their deep confidence in BioConsortia's science, strategy, and commercial momentum,' said Marcus Meadows-Smith, BioConsortia's CEO. 'Their investments total $95 million and bring BioConsortia to this exciting moment in the company's history.' The new funding will accelerate the global launch of Always-N™, BioConsortia's groundbreaking nitrogen-fixing seed treatment for industrial corn and support continued expansion of its discovery and development engine at the company's Davis, California headquarters. Always-N enables farmers to maintain crop yields while reducing reliance on synthetic nitrogen fertilizers—significantly lowering greenhouse gas emissions and improving soil health. Applied as a seed treatment, Always-N delivers consistent field performance and is the only nitrogen-fixing biofertilizer combining advanced gene editing and extended viability exceeding two years. "Synthetic nitrogen fertilizers are essential to modern agriculture, but their overuse comes at a steep environmental cost,' said Meadows-Smith. 'With Always-N, we offer a powerful, sustainable alternative—backed by cutting-edge science and built for real-world performance.' Roughly half of applied synthetic nitrogen is never absorbed by crops. Instead, it runs off into waterways or is broken down in soil, releasing nitrous oxide—a greenhouse gas 300 times more potent than CO₂. As regulatory and market pressure builds for climate-smart farming, demand for sustainable alternatives like Always-N is growing rapidly. Following its successful commercial debut in New Zealand in 2024, Always-N is now preparing for broader market entry, supported by key global partners including The Mosaic Company in row crops in the Americas. The new funding enables BioConsortia to scale manufacturing, build inventory, and expand market access in anticipation of the upcoming growing season. Always-N is powered by BioConsortia's discovery and development platform - an integrated engine using proprietary tools for microbial discovery, selection, and optimization. It begins with Advanced Microbial Selection™ (AMS) to identify high-performing plant-associated microbes, then uses GenExpress™ and GenePro™ tools to enhance traits such as nitrogen fixation, disease and pest control, and shelf-life. In addition to Always-N™, BioConsortia is advancing a robust pipeline of next-generation biostimulants, fungicides, nematicides, and insecticides—engineered for extended shelf life, ease of use, and superior field efficacy. Since its founding in 2014, BioConsortia has validated its platform across diverse crops, geographies, and soil types. Field trials have consistently demonstrated the efficacy of its microbial biofertilizers, fungicides, nematicides, and insecticides—delivering growers new tools for sustainable, high-yield farming. About BioConsortia At BioConsortia, we are pioneering the next generation of agricultural biologicals through cutting-edge microbial gene editing. Our breakthroughs in editing only the most stable microbes unlock unprecedented performance in nitrogen fixation, biocontrol, and biostimulants—delivering solutions that are more effective, more consistent, and easier to use than anything on the market today. By precisely enhancing natural microbial traits, we're creating products that outperform both traditional chemicals and first-generation biologicals—with longer shelf life, extended life on seed, robust field efficacy, and compatibility with existing farm systems. Our AMS platform supports rapid discovery and development of superior wild type microbial products, and our gene-edited innovations redefine what's possible in sustainable agriculture. Since its founding in 2014, BioConsortia has built a reputation for delivering science-driven, field-proven solutions across a wide range of crops, geographies, and growing conditions. Today, the company stands at the forefront of the agricultural biologicals revolution—offering farmers the tools to grow more with less, and do so sustainably.
Android Authority
18 minutes ago
- Android Authority
Here's how Android Identity Check will start taking advantage of your smartwatch (APK teardown)
Joe Maring / Android Authority TL;DR Identity Check offers an extra layer of protection when someone steals both your phone and your PIN. By requiring biometrics, Identity Check attempts to limit the harm bad actors could do. Google is working to let you bypass that biometric requirement when your device is connected to a trusted smartwatch. We all want our devices to be secure, but practical considerations mean we're often striking a balance between security and convenience. That's not a bad thing at all, as we don't always need to be taking advantage of every security protection available to us, and systems like Android's Identity Check are built for just this reason, letting us get away with just using a PIN or biometrics when we're at home, but beefing up security and insisting on both when outside a trusted location. Just last week, we looked at one way Identity Check could soon be changing, with the tool evolving to recognizing the presence of your connected smartwatch. At the time it wasn't yet clear exactly how the watch would alter Identity Check's behavior, but now it's starting to come into focus. ⚠️ An APK teardown helps predict features that may arrive on a service in the future based on work-in-progress code. However, it is possible that such predicted features may not make it to a public release. Identity Check is designed to help save your bacon when you're in just about the worst situation: someone else not only has your phone, but they also have your PIN. Maybe they shoulder-surfed while you were unlocking the phone, or used threats to get you to reveal it, but Identity Check is built to assume that your PIN's been compromised. That's exactly why it also insists upon biometric authentication when trying to access saved passwords or change critical security settings from anywhere other than a trusted location. Here are the strings we spotted last time we looked: Code Copy Text With your watch connected, Identity Check automatically recognizes you while maintaining your security even when you're not in a trusted location Protection on the move with watch Those made it clear that Google's working on a way for Identity Check to use the presence of a paired watch as a signal of trust, just in the way a location already can. But what we didn't have at the time was confirmation of how Identity Check would work differently when it sensed your watch. Looking through the new 25.31.30 beta release of Google Play Services, we've spotted an additional string that provides some answers: Code Copy Text Outside of trusted places like your home • If you have a connected watch, you can use either biometrics or your PIN • If you don't have a connected watch, you'll be required to use Fingerprint or Face Unlock There we go: When you're using Identity Check with a smartwatch it recognizes, you'll be able to bypass the need to enter a PIN, even when away from home. Basically, it's like two-factor authentication, and you've got to choose any two of the three: PIN, biometrics, or the presence of your watch. We supposed it is conceivable that someone manages to learn your PIN, steal your phone, and also take your smartwatch, so hopefully there's a setting to choose whether or not we want to take advantage of this option once it finally arrives. Follow
